BioMidwest

Found 82,071 articles

• Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

  4/9/2024

  In a significant stride towards transforming cardiovascular healthcare in concierge specialty and primary care offices, Exponential Health, an innovative concierge medical practice led by Dr. William Baer, is set to offer Cardio Diagnostics Holdings, Inc.’s clinical epigenetic-genetic cardiovascular tests, Epi+Gen CHD and PrecisionCHD, to their patients.

• Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinson’s Disease and Related Disorders

  4/9/2024

  Vanqua Bio announced that the first patient has been dosed in a first-in-human Phase 1 clinical study evaluating VQ-101 in healthy individuals and patients with various forms of Parkinson’s disease (PD).

• GE HealthCare to Announce First Quarter 2024 Results on April 30, 2024

  4/9/2024

  GE HealthCare, a leader in precision care innovation, will announce its first quarter 2024 financial results before the market opens on Tuesday, April 30, 2024.

• Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

  4/9/2024

  Cadrenal Therapeutics, Inc. announced that the United States Food and Drug Administration has granted tecarfarin Orphan Drug Designation for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device.

• NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes

  4/9/2024

  NeuroOne Medical Technologies Corporation, a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced the first implant of its OneRF™ Ablation electrode by doctors at a top ranked hospital in the US, as ranked by the US News & World Best Hospital Report in its 2023-2024 publication.

• Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery

  4/9/2024

  Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.

• MOLLI Surgical Unveils OncoPen, a New Surgical Tool for Empowering Precision and Confidence in the Operating Room

  4/9/2024

  MOLLI Surgical continues to push the boundaries of surgical care with the launch of OncoPen™, a minimally invasive surgical tool designed to empower surgeons and improve outcomes for patients affected with breast cancer.

• Neogen Announces Third-Quarter 2024 Results

  4/9/2024

  Neogen Corporation (NASDAQ: NEOG) announced today the results of the third quarter ended February 29, 2024.

• American Lung Association and LUNGevity Foundation Announce $3 Million Research Partnership to Intercept Lung Cancer

  4/9/2024

  Lung cancer remains the leading cause of cancer deaths in the United States, with someone diagnosed approximately every two minutes.

• Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

  4/9/2024

  Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, announced the appointment of Lori Kunkel, MD, to its Board of Directors.

• Centene Subsidiary Meridian in Michigan Awarded Michigan Medicaid Contracts

  4/9/2024

  Centene Corporation announced that its subsidiary, Meridian in Michigan, has been selected by the Michigan Department of Health and Human Services to continue to serve as a Medicaid health plan for the Comprehensive Health Care Program, which serves nearly 2 million Michiganders statewide.

• ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

  4/9/2024

  ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy ® .

• NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

  4/9/2024

  NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2023 for the period ended December 31, 2023.

• Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

  4/8/2024

  Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.

• LIB Therapeutics Announces Positive Results from LIBerate-HR Study: A 52-Week, Placebo-Controlled Registration-Enabling Trial of Lerodalcibep at Late-Breaking Session at American College of Cardiology 2024

  4/8/2024

  LIB Therapeutics Inc. announced positive results from two studies in the recently completed Phase 3 LIBerate registration-enabling program were presented at the American College of Cardiology 2024 in Atlanta, Georgia on April 6-8, 2024.

• Bio-Techne Surpasses 10,000 Peer-Reviewed Publications Citing RNAscope Technology

  4/8/2024

  Bio-Techne Corporation announced that Advanced Cell Diagnostics, part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology.

• Mesa Labs Announces Amendment to Credit Facility and Repurchase of Senior Convertible Notes

  4/8/2024

  Mesa Laboratories, Inc. announced the closing of its Amended and Restated Credit Agreement, which provides up to $200 million of senior secured debt through a syndicate of banks led by JPMORGAN CHASE BANK, N.A.

• Zura Bio Announces Robert Lisicki as CEO and Director

  4/8/2024

  Zura Bio Limited a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio.

• Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals

  4/8/2024

  Longeveron Inc. announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders.

• CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

  4/8/2024

  CoreRx, Inc. announced that it has completed its acquisition of Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics.